New treatment approved to treat ovarian cancer
Tesaro has announced that the European Commission (EC) has granted marketing authorization for Zejula (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy.
Comment: Zejula was approved by the FDA on 27 March 2017 and is marketed by Tesaro in the United States, where it is currently the most frequently prescribed PARP inhibitor for patients with ovarian cancer. Tesaro plans to launch Zejula in Germany and the UK this December 2017, with launches in additional European countries to follow beginning in 2018, based on local reimbursement and availability timelines. Germany and the UK are two of the 17 countries where Tesaro currently has a direct presence in Europe.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.